{"pmid":32503877,"title":"Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.","text":["Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.","Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation. Acalabrutinib, a selective BTK inhibitor, was administered off-label to 19 patients hospitalized with severe COVID-19 (11 on supplemental oxygen; 8 on mechanical ventilation), 18 of whom had increasing oxygen requirements at baseline. Over a 10-14 day treatment course, acalabrutinib improved oxygenation in a majority of patients, often within 1-3 days, and had no discernable toxicity. Measures of inflammation - C-reactive protein and IL-6 - normalized quickly in most patients, as did lymphopenia, in correlation with improved oxygenation. At the end of acalabrutinib treatment, 8/11 (72.7%) patients in the supplemental oxygen cohort had been discharged on room air, and 4/8 (50%) patients in the mechanical ventilation cohort had been successfully extubated, with 2/8 (25%) discharged on room air. Ex vivo analysis revealed significantly elevated BTK activity, as evidenced by autophosphorylation, and increased IL-6 production in blood monocytes from patients with severe COVID-19 compared with blood monocytes from healthy volunteers. These results suggest that targeting excessive host inflammation with a BTK inhibitor is a therapeutic strategy in severe COVID-19 and has led to a confirmatory international prospective randomized controlled clinical trial.","Sci Immunol","Roschewski, Mark","Lionakis, Michail S","Sharman, Jeff P","Roswarski, Joseph","Goy, Andre","Monticelli, M Andrew","Roshon, Michael","Wrzesinski, Stephen H","Desai, Jigar V","Zarakas, Marissa A","Collen, Jacob","Rose, Keith","Hamdy, Ahmed","Izumi, Raquel","Wright, George W","Chung, Kevin K","Baselga, Jose","Staudt, Louis M","Wilson, Wyndham H","32503877"],"abstract":["Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation. Acalabrutinib, a selective BTK inhibitor, was administered off-label to 19 patients hospitalized with severe COVID-19 (11 on supplemental oxygen; 8 on mechanical ventilation), 18 of whom had increasing oxygen requirements at baseline. Over a 10-14 day treatment course, acalabrutinib improved oxygenation in a majority of patients, often within 1-3 days, and had no discernable toxicity. Measures of inflammation - C-reactive protein and IL-6 - normalized quickly in most patients, as did lymphopenia, in correlation with improved oxygenation. At the end of acalabrutinib treatment, 8/11 (72.7%) patients in the supplemental oxygen cohort had been discharged on room air, and 4/8 (50%) patients in the mechanical ventilation cohort had been successfully extubated, with 2/8 (25%) discharged on room air. Ex vivo analysis revealed significantly elevated BTK activity, as evidenced by autophosphorylation, and increased IL-6 production in blood monocytes from patients with severe COVID-19 compared with blood monocytes from healthy volunteers. These results suggest that targeting excessive host inflammation with a BTK inhibitor is a therapeutic strategy in severe COVID-19 and has led to a confirmatory international prospective randomized controlled clinical trial."],"journal":"Sci Immunol","authors":["Roschewski, Mark","Lionakis, Michail S","Sharman, Jeff P","Roswarski, Joseph","Goy, Andre","Monticelli, M Andrew","Roshon, Michael","Wrzesinski, Stephen H","Desai, Jigar V","Zarakas, Marissa A","Collen, Jacob","Rose, Keith","Hamdy, Ahmed","Izumi, Raquel","Wright, George W","Chung, Kevin K","Baselga, Jose","Staudt, Louis M","Wilson, Wyndham H"],"date":"2020-06-07T11:00:00Z","year":2020,"_id":"32503877","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1126/sciimmunol.abd0110","locations":["Bruton"],"e_drugs":["acalabrutinib"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668892488360787968,"score":9.490897,"similar":[{"pmid":32345646,"title":"BTK inhibitors in cancer patients with COVID19: \"The winner will be the one who controls that chaos\" (Napoleon Bonaparte).","text":["BTK inhibitors in cancer patients with COVID19: \"The winner will be the one who controls that chaos\" (Napoleon Bonaparte).","As the SARS-CoV-2 (COVID19) pandemic spreads and the number of Bruton's tyrosine kinase inhibitor (BTKi)-treated COVID19 affected patients grows, we must consider the pros and cons of BTKi discontinuation for our patients. In favor of BTKi continuation, BTK plays an active role in macrophage polarization. By modulating key transcription factors, BTK may regulate macrophage polarization downstream of classic M1 and M2 polarizing stimuli and mitigate the hyperinflammatory state associated with COVID19. In favor of BTKi discontinuation, we note a potentially increased risk of secondary infections or impaired humoral immunity. We hypothesize that the potential benefit of blunting a hyper-inflammatory response to SARS-CoV-2 through attenuation of M1 polarization outweighs the potential risk of impaired humoral immunity, not to mention the risk of rapid progression of B-cell malignancy following BTKi interruption. Based on this, we suggest continuing BTKi in patients with COVID19.","Clin Cancer Res","Chong, Elise A","Roeker, Lindsey E","Shadman, Mazyar","Davids, Matthew S","Schuster, Stephen J","Mato, Anthony R","32345646"],"abstract":["As the SARS-CoV-2 (COVID19) pandemic spreads and the number of Bruton's tyrosine kinase inhibitor (BTKi)-treated COVID19 affected patients grows, we must consider the pros and cons of BTKi discontinuation for our patients. In favor of BTKi continuation, BTK plays an active role in macrophage polarization. By modulating key transcription factors, BTK may regulate macrophage polarization downstream of classic M1 and M2 polarizing stimuli and mitigate the hyperinflammatory state associated with COVID19. In favor of BTKi discontinuation, we note a potentially increased risk of secondary infections or impaired humoral immunity. We hypothesize that the potential benefit of blunting a hyper-inflammatory response to SARS-CoV-2 through attenuation of M1 polarization outweighs the potential risk of impaired humoral immunity, not to mention the risk of rapid progression of B-cell malignancy following BTKi interruption. Based on this, we suggest continuing BTKi in patients with COVID19."],"journal":"Clin Cancer Res","authors":["Chong, Elise A","Roeker, Lindsey E","Shadman, Mazyar","Davids, Matthew S","Schuster, Stephen J","Mato, Anthony R"],"date":"2020-04-30T11:00:00Z","year":2020,"_id":"32345646","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1158/1078-0432.CCR-20-1427","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138495460048896,"score":334.0252},{"pmid":32275812,"pmcid":"PMC7169476","title":"Compassionate Use of Remdesivir for Patients with Severe Covid-19.","text":["Compassionate Use of Remdesivir for Patients with Severe Covid-19.","BACKGROUND: Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. METHODS: We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day. RESULTS: Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. CONCLUSIONS: In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.).","N Engl J Med","Grein, Jonathan","Ohmagari, Norio","Shin, Daniel","Diaz, George","Asperges, Erika","Castagna, Antonella","Feldt, Torsten","Green, Gary","Green, Margaret L","Lescure, Francois-Xavier","Nicastri, Emanuele","Oda, Rentaro","Yo, Kikuo","Quiros-Roldan, Eugenia","Studemeister, Alex","Redinski, John","Ahmed, Seema","Bernett, Jorge","Chelliah, Daniel","Chen, Danny","Chihara, Shingo","Cohen, Stuart H","Cunningham, Jennifer","D'Arminio Monforte, Antonella","Ismail, Saad","Kato, Hideaki","Lapadula, Giuseppe","L'Her, Erwan","Maeno, Toshitaka","Majumder, Sumit","Massari, Marco","Mora-Rillo, Marta","Mutoh, Yoshikazu","Nguyen, Duc","Verweij, Ewa","Zoufaly, Alexander","Osinusi, Anu O","DeZure, Adam","Zhao, Yang","Zhong, Lijie","Chokkalingam, Anand","Elboudwarej, Emon","Telep, Laura","Timbs, Leighann","Henne, Ilana","Sellers, Scott","Cao, Huyen","Tan, Susanna K","Winterbourne, Lucinda","Desai, Polly","Mera, Robertino","Gaggar, Anuj","Myers, Robert P","Brainard, Diana M","Childs, Richard","Flanigan, Timothy","32275812"],"abstract":["BACKGROUND: Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. METHODS: We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day. RESULTS: Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. CONCLUSIONS: In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)."],"journal":"N Engl J Med","authors":["Grein, Jonathan","Ohmagari, Norio","Shin, Daniel","Diaz, George","Asperges, Erika","Castagna, Antonella","Feldt, Torsten","Green, Gary","Green, Margaret L","Lescure, Francois-Xavier","Nicastri, Emanuele","Oda, Rentaro","Yo, Kikuo","Quiros-Roldan, Eugenia","Studemeister, Alex","Redinski, John","Ahmed, Seema","Bernett, Jorge","Chelliah, Daniel","Chen, Danny","Chihara, Shingo","Cohen, Stuart H","Cunningham, Jennifer","D'Arminio Monforte, Antonella","Ismail, Saad","Kato, Hideaki","Lapadula, Giuseppe","L'Her, Erwan","Maeno, Toshitaka","Majumder, Sumit","Massari, Marco","Mora-Rillo, Marta","Mutoh, Yoshikazu","Nguyen, Duc","Verweij, Ewa","Zoufaly, Alexander","Osinusi, Anu O","DeZure, Adam","Zhao, Yang","Zhong, Lijie","Chokkalingam, Anand","Elboudwarej, Emon","Telep, Laura","Timbs, Leighann","Henne, Ilana","Sellers, Scott","Cao, Huyen","Tan, Susanna K","Winterbourne, Lucinda","Desai, Polly","Mera, Robertino","Gaggar, Anuj","Myers, Robert P","Brainard, Diana M","Childs, Richard","Flanigan, Timothy"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275812","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1056/NEJMoa2007016","link_comment_in":"32321732","locations":["United States","Canada","Japan"],"countries":["United States","Canada","Japan"],"countries_codes":["USA|United States","CAN|Canada","JPN|Japan"],"e_drugs":["remdesivir"],"topics":["Treatment"],"weight":1,"_version_":1666138491698806786,"score":233.61049},{"pmid":32448770,"title":"Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.","text":["Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.","BACKGROUND: Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking downstream pro-inflammatory effects of IL-6. In preliminary reports it was suggested to be beneficial in patients with severe COVID-19. METHODS: In this open-label prospective study we describe clinical characteristics and outcome of 51 patients hospitalized with confirmed and severe COVID-19 pneumonia treated with tocilizumab intravenously. All patients had elevated IL-6 plasma level (>40 pg/mL) and oxygen saturation <93% in ambient air. Clinical outcomes, oxygen support, laboratory data and adverse events were collected over a follow-up of 30 days. RESULTS: Forty-five patients (88%) were on high-flow oxygen supplementation, six of whom with invasive ventilation. From baseline to day 7 after tocilizumab we observed a dramatic drop of body temperature and CRP value with a significant increase in lymphocyte count (p<0.001). Over a median follow-up time of 34 days from tocilizumab, 34 patients (67%) showed an improvement in their clinical severity class; 31 were discharged; 17 (33%) showed a worsening of their clinical status, of these 14 died (27%). The mortality rate was significantly associated with mechanical ventilation at baseline (83.3% vs 20% of patients on non-invasive oxygen support; p=0.0001). The most frequent side effects were an increase of hepatic enzymes (29%), thrombocytopenia (14%), and serious bacterial and fungal infections (27%). CONCLUSION: Tocilizumab exerts a rapidly beneficial effect on fever and inflammatory markers, although no significant impact on the clinical outcome can be inferred by our results. Critically ill patients seem to have a high risk of serious infections with this drug.","Eur J Intern Med","Morena, Valentina","Milazzo, Laura","Oreni, Letizia","Bestetti, Giovanna","Fossali, Tommaso","Bassoli, Cinzia","Torre, Alessandro","Cossu, Maria Vittoria","Minari, Caterina","Ballone, Elisabetta","Perotti, Andrea","Mileto, Davide","Niero, Fosca","Merli, Stefania","Foschi, Antonella","Vimercati, Stefania","Rizzardini, Giuliano","Sollima, Salvatore","Bradanini, Lucia","Galimberti, Laura","Colombo, Riccardo","Micheli, Valeria","Negri, Cristina","Ridolfo, Anna Lisa","Meroni, Luca","Galli, Massimo","Antinori, Spinello","Corbellino, Mario","32448770"],"abstract":["BACKGROUND: Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors blocking downstream pro-inflammatory effects of IL-6. In preliminary reports it was suggested to be beneficial in patients with severe COVID-19. METHODS: In this open-label prospective study we describe clinical characteristics and outcome of 51 patients hospitalized with confirmed and severe COVID-19 pneumonia treated with tocilizumab intravenously. All patients had elevated IL-6 plasma level (>40 pg/mL) and oxygen saturation <93% in ambient air. Clinical outcomes, oxygen support, laboratory data and adverse events were collected over a follow-up of 30 days. RESULTS: Forty-five patients (88%) were on high-flow oxygen supplementation, six of whom with invasive ventilation. From baseline to day 7 after tocilizumab we observed a dramatic drop of body temperature and CRP value with a significant increase in lymphocyte count (p<0.001). Over a median follow-up time of 34 days from tocilizumab, 34 patients (67%) showed an improvement in their clinical severity class; 31 were discharged; 17 (33%) showed a worsening of their clinical status, of these 14 died (27%). The mortality rate was significantly associated with mechanical ventilation at baseline (83.3% vs 20% of patients on non-invasive oxygen support; p=0.0001). The most frequent side effects were an increase of hepatic enzymes (29%), thrombocytopenia (14%), and serious bacterial and fungal infections (27%). CONCLUSION: Tocilizumab exerts a rapidly beneficial effect on fever and inflammatory markers, although no significant impact on the clinical outcome can be inferred by our results. Critically ill patients seem to have a high risk of serious infections with this drug."],"journal":"Eur J Intern Med","authors":["Morena, Valentina","Milazzo, Laura","Oreni, Letizia","Bestetti, Giovanna","Fossali, Tommaso","Bassoli, Cinzia","Torre, Alessandro","Cossu, Maria Vittoria","Minari, Caterina","Ballone, Elisabetta","Perotti, Andrea","Mileto, Davide","Niero, Fosca","Merli, Stefania","Foschi, Antonella","Vimercati, Stefania","Rizzardini, Giuliano","Sollima, Salvatore","Bradanini, Lucia","Galimberti, Laura","Colombo, Riccardo","Micheli, Valeria","Negri, Cristina","Ridolfo, Anna Lisa","Meroni, Luca","Galli, Massimo","Antinori, Spinello","Corbellino, Mario"],"date":"2020-05-26T11:00:00Z","year":2020,"_id":"32448770","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.ejim.2020.05.011","keywords":["covid-19","il-6 inhibitors","tocilizumab"],"locations":["thrombocytopenia","Milan","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1667785214012686336,"score":220.22151},{"pmid":32484930,"title":"''Tociluzumab challenge: A series of cytokine storm therapy experience in hospitalized Covid-19 pneumonia patients''.","text":["''Tociluzumab challenge: A series of cytokine storm therapy experience in hospitalized Covid-19 pneumonia patients''.","OBJECTIVE: To recognize the period of exaggerated cytokine response in patients with Coronavirus disease 2019 (COVID-19) pneumonia, and to describe the clinical outcomes of using tocilizumab as a treatment option. METHODS: The data of 12 adult COVID-19 pneumonia patients who were followed in the inpatient clinics of Biruni University Medical Faculty Hospital (Istanbul, Turkey) were retrospectively analyzed. Diagnostic tests, laboratory examinations, clinical findings and computed tomography of the thorax imaging results were evaluated. RESULTS: A dramatic laboratory and clinical improvement was observed in 83% (10/12) of patients after tocilizumab. In 17% (2/12) of our patients, short-term ventilator support was required in the intensive care unit. The longest hospital stay was 18 days. However, in the end, all of our patients were discharged home with health. While arterial oxygen saturations (87.58+/-3.12%) dropped in room air in the pre-tocilizumab period, post-tocilizumab they normalized in all patients (94.42+/-1%). None of them had fever after tocilizumab treatment and the levels of c-reactive protein (13.08+/-12.89) were almost within normal limits. Eosinophil values were quite low at the time of diagnosis (10+/-17.06), but increased significantly post-tocilizumab (155.33+/-192.69). CONCLUSION: There is currently no proven treatment for COVID-19 induced by novel coronavirus SARS-CoV-2. Based on our experience with twelve adult COVID-19 pneumonia patients, we can say that tocilizumab, an IL-6 inhibitor, is more beneficial in preventing the damage caused by excessive cytokine response in the body if administered at the right time and provides clinical and radiological recovery. This article is protected by copyright. All rights reserved.","J Med Virol","Borku Uysal, Betul","Ikitimur, Hande","Yavuzer, Serap","Ikitimur, Baris","Uysal, Harun","Islamoglu, Mehmet Sami","Ozcan, Erkan","Aktepe, Emre","Yavuzer, Hakan","Cengiz, Mahir","32484930"],"abstract":["OBJECTIVE: To recognize the period of exaggerated cytokine response in patients with Coronavirus disease 2019 (COVID-19) pneumonia, and to describe the clinical outcomes of using tocilizumab as a treatment option. METHODS: The data of 12 adult COVID-19 pneumonia patients who were followed in the inpatient clinics of Biruni University Medical Faculty Hospital (Istanbul, Turkey) were retrospectively analyzed. Diagnostic tests, laboratory examinations, clinical findings and computed tomography of the thorax imaging results were evaluated. RESULTS: A dramatic laboratory and clinical improvement was observed in 83% (10/12) of patients after tocilizumab. In 17% (2/12) of our patients, short-term ventilator support was required in the intensive care unit. The longest hospital stay was 18 days. However, in the end, all of our patients were discharged home with health. While arterial oxygen saturations (87.58+/-3.12%) dropped in room air in the pre-tocilizumab period, post-tocilizumab they normalized in all patients (94.42+/-1%). None of them had fever after tocilizumab treatment and the levels of c-reactive protein (13.08+/-12.89) were almost within normal limits. Eosinophil values were quite low at the time of diagnosis (10+/-17.06), but increased significantly post-tocilizumab (155.33+/-192.69). CONCLUSION: There is currently no proven treatment for COVID-19 induced by novel coronavirus SARS-CoV-2. Based on our experience with twelve adult COVID-19 pneumonia patients, we can say that tocilizumab, an IL-6 inhibitor, is more beneficial in preventing the damage caused by excessive cytokine response in the body if administered at the right time and provides clinical and radiological recovery. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Borku Uysal, Betul","Ikitimur, Hande","Yavuzer, Serap","Ikitimur, Baris","Uysal, Harun","Islamoglu, Mehmet Sami","Ozcan, Erkan","Aktepe, Emre","Yavuzer, Hakan","Cengiz, Mahir"],"date":"2020-06-03T11:00:00Z","year":2020,"_id":"32484930","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1002/jmv.26111","keywords":["covid-19","sars cov-2","tocilizumab","pneumonia"],"locations":["Istanbul","Turkey","Tociluzumab"],"countries":["Turkey"],"countries_codes":["TUR|Turkey"],"e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1668704334459699202,"score":178.97855},{"pmid":32359035,"title":"Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.","text":["Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19.","OBJECTIVES: No agent has yet been proven to be effective for the treatment of patients with severe COVID-19. METHODS: We conducted a pilot prospective open, single-arm multicentre study on off-label use of tocilizumab (TCZ) involving 63 hospitalised adult patients (56 males, age 62.6+/-12.5) with severe COVID-19. Clinical and laboratory parameters were prospectively collected at baseline, day 1, 2, 7 and 14. No moderate-to severe adverse events attributable to TCZ were recorded. RESULTS: We observed a significant improvement in the levels of ferritin, C-reactive protein, D-dimer. The ratio of the partial pressure of oxygen (Pa02) to the fraction of inspired oxygen (Fi02) improved (mean+/-SD Pa02/Fi02 at admission: 152+/-53; at day 7: 283.73 +/- 115.9, at day 14: 302.2 +/- 126, p<0.05). The overall mortality was 11%; D-dimer level at baseline, but not IL-6 levels were predictors of mortality. TCZ administration within 6 days from admission in the hospital was associated with an increased likelihood of survival (HR 2.2 95%CI 1.3-6.7, p<0.05). CONCLUSIONS: In hospitalised adult patients with severe COVID-19, TCZ could be a safe option. An improvement in respiratory and laboratory parameters was observed. Future controlled trials in patients with severe illness are urgently needed to confirm the definite benefit with IL-6 target therapy.","Clin Exp Rheumatol","Sciascia, Savino","Apra, Franco","Baffa, Alessandra","Baldovino, Simone","Boaro, Daniela","Boero, Roberto","Bonora, Stefano","Calcagno, Andrea","Cecchi, Irene","Cinnirella, Giacoma","Converso, Marcella","Cozzi, Martina","Crosasso, Paola","De Iaco, Fabio","Di Perri, Giovanni","Eandi, Mario","Fenoglio, Roberta","Giusti, Massimo","Imperiale, Daniele","Imperiale, Gianlorenzo","Livigni, Sergio","Manno, Emilpaolo","Massara, Carlo","Milone, Valeria","Natale, Giuseppe","Navarra, Mauro","Oddone, Valentina","Osella, Sara","Piccioni, Pavilio","Radin, Massimo","Roccatello, Dario","Rossi, Daniela","32359035"],"abstract":["OBJECTIVES: No agent has yet been proven to be effective for the treatment of patients with severe COVID-19. METHODS: We conducted a pilot prospective open, single-arm multicentre study on off-label use of tocilizumab (TCZ) involving 63 hospitalised adult patients (56 males, age 62.6+/-12.5) with severe COVID-19. Clinical and laboratory parameters were prospectively collected at baseline, day 1, 2, 7 and 14. No moderate-to severe adverse events attributable to TCZ were recorded. RESULTS: We observed a significant improvement in the levels of ferritin, C-reactive protein, D-dimer. The ratio of the partial pressure of oxygen (Pa02) to the fraction of inspired oxygen (Fi02) improved (mean+/-SD Pa02/Fi02 at admission: 152+/-53; at day 7: 283.73 +/- 115.9, at day 14: 302.2 +/- 126, p<0.05). The overall mortality was 11%; D-dimer level at baseline, but not IL-6 levels were predictors of mortality. TCZ administration within 6 days from admission in the hospital was associated with an increased likelihood of survival (HR 2.2 95%CI 1.3-6.7, p<0.05). CONCLUSIONS: In hospitalised adult patients with severe COVID-19, TCZ could be a safe option. An improvement in respiratory and laboratory parameters was observed. Future controlled trials in patients with severe illness are urgently needed to confirm the definite benefit with IL-6 target therapy."],"journal":"Clin Exp Rheumatol","authors":["Sciascia, Savino","Apra, Franco","Baffa, Alessandra","Baldovino, Simone","Boaro, Daniela","Boero, Roberto","Bonora, Stefano","Calcagno, Andrea","Cecchi, Irene","Cinnirella, Giacoma","Converso, Marcella","Cozzi, Martina","Crosasso, Paola","De Iaco, Fabio","Di Perri, Giovanni","Eandi, Mario","Fenoglio, Roberta","Giusti, Massimo","Imperiale, Daniele","Imperiale, Gianlorenzo","Livigni, Sergio","Manno, Emilpaolo","Massara, Carlo","Milone, Valeria","Natale, Giuseppe","Navarra, Mauro","Oddone, Valentina","Osella, Sara","Piccioni, Pavilio","Radin, Massimo","Roccatello, Dario","Rossi, Daniela"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359035","source":"PubMed","week":"202018|Apr 27 - May 03","e_drugs":["tocilizumab"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138495359385600,"score":175.12523}]}